Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Times cited: 27
- Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. British Journal of Haematology. 2019 Information Resource GET IT
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
American Journal of Hematology.
Times cited: 13